-

Forge Biologics to Present at Jefferies Virtual Healthcare Conference

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that its CEO, President and Co-Founder Timothy J. Miller, Ph.D., will present at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021. Dr. Miller will provide a company overview, detailing the company’s growth from its launch in July, 2020 with $40 million in Series A financing, to an additional $120 million Series B round in less than a year.

Jefferies Virtual Healthcare Conference—June 1-4, 2021

Date: Friday, June 4, 2021
Time: 11:30-11:55am EST
Webcast: virtual webinar link here or https://wsw.com/webcast/jeff174/forge/1996245
Webcast replay link: A replay will be accessible on the Insights page of the company website at https://insights.forgebiologics.com/

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit www.forgebiologics.com.

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Forge Biologics


Release Summary
Forge to Present at Jefferies Healthcare Conference
Release Versions

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Avista Therapeutics and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

PITTSBURGH & COLUMBUS, Ohio--(BUSINESS WIRE)--Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene...

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help...

Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ pl...
Back to Newsroom